Name: 글로벌 시장 동향
SKU: PH7
Availability: InStock

보고서 요약(국문)

시장 개요
전 세계 전립선암 시장은 2022년 117억 달러 규모에 달했으며, 2030년까지 216억 달러에 이르러 높은 성장세를 보일 것으로 예상됩니다. 전립선암 시장은 2023년부터 2030년까지 연평균 8.1%의 성장률을 기록할 것으로 전망됩니다.
전립선암은 남성에게 발생하는 두 번째로 흔한 암으로, 피부암 다음으로 높은 발병률을 보입니다. 전립선암 발병률 증가, 조기 진단에 대한 인식 제고, 그리고 의료 분야의 발전된 기술들이 시장 성장을 견인하고 있습니다.
새로운 제품 출시 또한 예측 기간 동안 전 세계 전립선암 시장 성장을 촉진할 것으로 예상됩니다. 예를 들어, 2022년 3월 미국 식품의약국(FDA)은 스위스-미국 다국적 제약회사인 노바티스의 플루빅토(루테튬 Lu 177 비피보티드 테트라세탄)를 전립선 특이 막 항원 양성 전이성 거세 저항성 전립선암(PSMA-PCPC)이라는 특정 유형의 진행성 전립선암을 앓는 성인 환자 치료제로 승인했습니다.

시장 동향
전립선암 발병률 증가가 예측 기간 동안 세계 전립선암 시장 성장을 견인할 전망입니다.
전립선암 발병률 증가는 예측 기간 동안 세계 전립선암 시장 성장을 주도할 것으로 예상됩니다. 예를 들어, 미국 임상종양학회(ASCO)에 따르면 전립선암은 피부암과 더불어 남성에게 가장 흔한 암입니다.
2023년 미국에서는 약 288,300명의 남성이 전립선암 진단을 받을 것으로 추정됩니다. 전 세계적으로는 2020년에 약 1,414,259명이 전립선암 진단을 받았습니다. 전립선암은 세계에서 네 번째로 흔한 암입니다.
전립선암 환자 지원을 위한 다양한 노력들이 증가함에 따라 향후 몇 년 동안 세계 전립선암 시장은 유망한 성장 기회를 맞이할 것으로 예상됩니다. 예를 들어, 2022년 4월 마운트 시나이 병원의 밀턴 앤 캐롤 페트리 비뇨기과는 흑인 커뮤니티의 전립선 건강 증진을 위해 마운트 시나이 로버트 F. 스미스 이동식 전립선암 검진 차량을 설립했습니다.
COVID-19 영향 분석
COVID-19 분석에는 COVID-19 이전 시나리오, COVID-19 시나리오, COVID-19 이후 시나리오와 함께 가격 변동(팬데믹 기간 및 이후의 가격 변화를 COVID-19 이전 시나리오와 비교), 수요-공급 스펙트럼(거래 제한, 봉쇄 및 그로 인한 문제로 인한 수요와 공급의 변화), 정부 정책(정부 기관의 시장, 부문 또는 산업 활성화 정책) 및 제조업체 전략적 이니셔티브(제조업체가 COVID-19 문제를 완화하기 위해 취한 조치)가 포함됩니다.

러시아-우크라이나 전쟁 영향 분석
우크라이나 전쟁으로 인해 혼란이 가중되고 수백만 명의 사람들이 삶의 터전을 잃었습니다. 수많은 우크라이나인들이 서부 지역으로 피난하거나 유럽 및 해외 난민이 되었습니다. 그중에는 전립선암 환자들도 있었는데, 이들은 극심한 질병과 난민 생활이라는 이중고에 직면했습니다.
우크라이나의 암 전문 병원들이 버려지거나 공격을 받는 가운데, 국경 너머에서 제재와 인플레이션에 시달리는 우크라이나 환자들은 언제 치료를 받을 수 있을지조차 불확실한 상황입니다.
글로벌 경기 침체 영향 분석
의료 산업 역시 경기 침체의 영향을 완전히 피할 수는 없습니다. 과거 경기 침체기에는 의료기관들이 인력 감축과 해고를 경험했습니다. 하지만 의료 산업은 필수적인 특성 덕분에 다른 산업보다 상대적으로 잘 버텨왔습니다. 그럼에도 불구하고 인플레이션이 지속적으로 상승하면서 경기 침체의 위험은 시장을 위협하고 있습니다.
지난 2년간 선진국의 높은 인플레이션으로 인해 전반적인 물가가 급등하면서 경기 침체에 대한 우려가 더욱 커지고 있습니다. 누적적으로 악화되는 전반적인 구매 통제는 특히 신흥 경제국에 영향을 미칠 것으로 예상되며, 여러 면에서 도움이 될 것으로 여겨집니다.
인공지능 영향 분석
인공지능은 전립선암 진단 및 신약 개발에 대한 적용이 증가함에 따라 예측 기간 동안 세계 전립선암 시장에 긍정적인 영향을 미칠 것으로 예상됩니다. 예를 들어, AI 모델은 비침습적 방사선 영상(초음파 및 MRI)과 전립선 생검을 통해 얻은 조직병리학적 영상에서 암의 진행 정도를 진단하고 등급을 매기는 데 도움을 줄 수 있습니다.
세분화 분석
세계 전립선암 시장은 치료 유형, 최종 사용자 및 지역별로 세분화됩니다.
화학요법 부문은 세계 시장의 30.6%를 차지할 것으로 예상됩니다.
화학요법 부문은 해당 분야의 연구 개발 증가로 인해 세계 전립선암 시장의 약 30.6%를 차지할 것으로 예상됩니다. 예를 들어, 2023년 2월, 기초 및 중개 연구에 집중하는 비영리 의료 연구 기관인 샌포드 번햄 프레비스(Sanford Burnham Prebys)의 연구원들은 PI5P4Kα라는 단일 효소를 표적으로 삼아 전립선암을 치료할 수 있다는 사실을 발견했습니다.
지역 분석
유럽은 예측 기간 동안 전 세계 전립선암 시장에서 두 번째로 큰 점유율을 차지할 것으로 예상됩니다.
전립선암 발병 사례 증가와 전립선암 퇴치를 위한 노력으로 인해 유럽은 전 세계 전립선암 시장의 약 26.8%를 차지할 것으로 예상됩니다. 예를 들어, 유럽 제약산업협회(EFPIA)에 따르면 유럽에서는 3천만 명이 넘는 남성이 평생 동안 전립선암 진단을 받고 매년 7만 5천 명 이상의 남성이 전립선암으로 사망합니다.

또한, EU4Health 프로그램의 도입으로 12개국 25개 기관이 참여하는 야심찬 3년 프로젝트인 PRAISE-U(유럽 연합 내 전립선암 인식 및 선별검사 이니셔티브)가 지원되었습니다. PRAISE-U의 목표는 과잉 진단 및 과잉 치료를 방지하면서 전립선암으로 인한 사망률과 이환율을 낮추기 위해 EU 내 국가별 맞춤형 비용 효율적인 전립선암 조기 진단 알고리즘을 개발하는 것입니다.
경쟁 환경
시장의 주요 글로벌 기업으로는 Johnson & Johnson, Astella, Inc., Sanofi Aventis, IPSEN, Bayer AG, AstraZeneca, Valent Pharmaceuticals LLC, Novartis International AG, Clovis Oncology Inc. 등이 있습니다.
보고서 구매 이유

• 치료 유형, 최종 사용자 및 지역별 글로벌 전립선암 시장 세분화를 시각화하고 주요 상업적 자산과 기업을 파악하기 위함입니다.

• 트렌드 분석 및 공동 개발을 통해 상업적 기회를 파악합니다.

• 모든 세그먼트를 포함한 전립선암 시장 관련 다양한 데이터가 담긴 엑셀 데이터 시트를 제공합니다.

• 심층적인 질적 인터뷰와 연구를 바탕으로 종합적인 분석 결과를 담은 PDF 보고서를 제공합니다.

• 주요 업체들의 핵심 제품을 모두 포함한 제품 맵핑 자료를 엑셀 파일로 제공합니다.

글로벌 전립선암 시장 보고서는 약 53개의 표, 54개의 그림, 195페이지 분량입니다.
주요 고객 (2023년 기준)
• 제조업체/구매자
• 산업 투자자/투자은행
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Market Overview
The Global Prostate Cancer Market reached US$ 11.7 billion in 2022 and is projected to witness lucrative growth by reaching US$ 21.6 billion by 2030. The Prostate Cancer Market is expected to exhibit a CAGR of 8.1% from 2023 to 2030.
Prostate cancer is the second-most typical cancer arising in males, behind skin cancer. The growing prevalence of prostate cancer, raising awareness concerning early diagnosis, and the availability of sophisticated methods present in the medical domain are driving market growth.
The increasing product introductions also drive the global prostate cancer market during the forecast period. For instance, in March 2022, the US FDA authorized Novartis, a Swiss-American multinational pharmaceutical corporation's Pluvicto (lutetium Lu 177 vipivotide tetraxetan) indicated for the therapy of adult individuals suffering from a specific kind of progressive cancer named prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer.
Market Dynamics
The Growing Cases of Prostate Cancer are Driving the Global Prostate Cancer Market in the Forecast Period
The growing incidences of prostate cancer drive the global market during the forecast period. For instance, according to the American Society of Clinical Oncology (ASCO), prostate cancer, besides skin cancer, is the most typical cancer in males.
In 2023, an estimated 288,300 males in the United States will be detected with prostate cancer. While, globally, an estimated 1,414,259 individuals were seen with prostate cancer in 2020. Prostate cancer is the fourth most typically detected cancer in the world.
The Increasing Initiatives are Providing the Global Prostate Cancer Market with Prospective Growth Opportunities
The increasing initiatives to support prostate cancer patients present the Global Prostate Cancer Market with lucrative growth opportunities in the upcoming years. For instance, in April 2022, the Milton and Carroll Petrie Department of Urology at Mount Sinai established the Mount Sinai Robert F. Smith Mobile Prostate Cancer Screening Unit to help prostate health in the Black community.
COVID-19 Impact Analysis
The COVID-19 analysis includes Pre-COVID Scenario, COVID Scenario, and Post-COVID Scenario along with Pricing Dynamics (Including pricing change during and post-pandemic comparing it to pre-COVID scenarios), Demand-Supply Spectrum (Shift in demand and supply owing to trading restrictions, lockdown, and subsequent issues), Government Initiatives (Initiatives to revive market, sector or Industry by Government Bodies) and Manufacturers Strategic Initiatives (What manufacturers did to mitigate the COVID issues will be covered here).
Russia-Ukraine War Impact Analysis
As the warfare in Ukraine released disorder and uprooted millions of individuals, numerous Ukrainians had to escape to the western region of the nation and became refugees in Europe and outside. Among them were individuals with prostate cancer, who encountered a fierce one-two force of extreme sickness and exile.
And while cancer hospitals in Ukraine are being deserted or even attacked, Ukrainian patients across the boundary, struck by sanctions and inflation, even encounter an indefinite future for their care.
Global Recession Impact Analysis
The healthcare industry is not completely immune to recession, as healthcare institutions thought firings and employment during past financial downturns. That stated, the industry does cope finer than other sectors because of its essential nature. However, the danger of recession threatens the market as inflation persists increasing.
The elevated extent of tension about the persistent recession as the high inflation in developed countries worldwide has transpired in a general cost surge over the past two years. The cumulatively deteriorating general purchasing control is anticipated to affect growing economies particularly and is considered helpful in numerous ways.
Artificial Intelligence Impact Analysis
Artificial intelligence positively impacts the Global Prostate Cancer Market during the forecast period, owing to its increased application in prostate cancer diagnosis and drug development. For instance, ai models can assist in diagnosing and grading cancer aggressiveness on non-invasive radiology pictures (Ultrasound and MRI), and on histopathology images obtained via prostate biopsy.
Segment Analysis
The Global Prostate Cancer Market is segmented based on therapy type, end-user, and region.
The Chemotherapy Segment is Estimated To Hold a 30.6% Share of the Global Market.
The chemotherapy segment is estimated to hold about 30.6% of the global prostate cancer market owing to the increasing research development in the part. For instance, in February 2023, investigators from Sanford Burnham Prebys, a non-profit medical research institute concentrating on fundamental and translational studies, found that prostate cancer can be killed by targeting a single enzyme called PI5P4Kα.
Geographical Analysis
Europe is Estimated to Hold the Second-Largest Share of the Global Prostate Cancer Market During the Forecast Period.
Owing to the growing number of prostate cancer cases and initiatives to battle against prostate cancer, Europe is estimated to hold about 26.8% of the global prostate cancer market. For instance, according to the European Federation of Pharmaceutical Industries and Associations, over 30 million males in Europe are detected with prostate cancer in their lifetime and every year more than 75,000 males die from prostate cancer in Europe.
Moreover, the introduction of the EU4Health program has supported PRAISE-U (PRostate cancer Awareness and Initiative for Screening in the European Union), an ambitious three-year task concerning 25 organizations from 12 nations. PRAISE-U’s task is to develop a nationally-tailored cost-effective early diagnosis algorithm for prostate cancer filtering in the EU to decrease mortality and morbidity induced by prostate cancer while evading overdiagnosis and overtreatment.
Competitive Landscape
The major global players in the market include Johnson & Johnson, Astella, Inc., Sanofi Aventis, IPSEN, Bayer AG, AstraZeneca, Valent Pharmaceuticals LLC, Novartis International AG, and Clovis Oncology Inc., among others.
Why Purchase the Report?
• To visualize the Global Prostate Cancer Market segmentation based on therapy type, end-user, and region and understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous prostate cancer market-level data points with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.
The Global Prostate Cancer Market Report Would Provide Approximately 53 Tables, 54 Figures And 195 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Therapy Type
3.2. Snippet by End User
3.3. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing Product Approvals
4.1.1.2. Growing Prostate Cancer Prevalence
4.1.2. Restraints
4.1.2.1. Stringent Regulatory Authorities
4.1.3. Opportunity
4.1.4. Government Initiatives
4.1.5. Impact Analysis
5. Industry Analysis
5.1. Porter’s 5 Forces Analysis
5.2. Regulatory Analysis
5.3. Pricing Analysis
5.4. Patent Analysis
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID-19
6.1.2. Scenario During COVID-19
6.1.3. Post COVID-19 & Future Scenario
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers’ Strategic Initiatives
6.6. Conclusion
7. Russia-Ukraine War Analysis
8. Global Recession Analysis
9. Artificial Intelligence Impact Analysis
10. By Therapy Type
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
10.1.2. Market Attractiveness Index, By Therapy Type
10.2. Hormone therapy
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Chemotherapy
10.4. Immunotherapy
10.5. Radiation
10.6. External-beam radiation therapy
10.7. Brachytherapy
10.8. Focal therapies
10.9. Cryosurgery
10.10. High-intensity focused ultrasound (HIFU)
11. By End User
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.1.2. Market Attractiveness Index, By End User
11.2. Hospitals
11.2.1. Introduction
11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.3. Ambulatory Surgical Centers
11.4. Specialty Clinics
11.5. Cancer Rehabilitation Centers
12. By Region
12.1. Introduction
12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
12.1.2. Market Attractiveness Index, By Region
12.2. North America
12.2.1. Introduction
12.2.2. Key Region-Specific Dynamics
12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.2.5.1. The U.S.
12.2.5.2. Canada
12.2.5.3. Mexico
12.3. Europe
12.3.1. Introduction
12.3.2. Key Region-Specific Dynamics
12.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
12.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
12.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.3.5.1. Germany
12.3.5.2. The U.K.
12.3.5.3. France
12.3.5.4. Italy
12.3.5.5. Spain
12.3.5.6. Rest of Europe
12.4. South America
12.4.1. Introduction
12.4.2. Key Region-Specific Dynamics
12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.4.5.1. Brazil
12.4.5.2. Argentina
12.4.5.3. Rest of South America
12.5. Asia-Pacific
12.5.1. Introduction
12.5.2. Key Region-Specific Dynamics
12.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
12.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
12.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.5.5.1. China
12.5.5.2. India
12.5.5.3. Japan
12.5.5.4. Australia
12.5.5.5. Rest of Asia-Pacific
12.6. Middle East and Africa
12.6.1. Introduction
12.6.2. Key Region-Specific Dynamics
12.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
12.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
13. Competitive Landscape
13.1. Competitive Scenario
13.2. Market Share Analysis
13.3. Mergers and Acquisitions Analysis
14. Company Profiles
14.1. Johnson & Johnson
14.1.1. Company Overview
14.1.2. Therapy Type Portfolio and Description
14.1.3. Financial Overview
14.1.4. Key Developments
14.2. Astella, Inc.
14.3. Sanofi Aventis
14.4. IPSEN
14.5. Bayer AG
14.6. AstraZeneca
14.7. Valent Pharmaceuticals LLC
14.8. Sanofi-Aventis
14.9. Pfizer Inc.
14.10. Novartis International AG
LIST NOT EXHAUSTIVE
15. Appendix
15.1. About Us and Services
15.2. Contact Us

언급된 주요 기업들

Johnson & Johnson, 4.	Key Developments, Astella, Inc., Sanofi Aventis, IPSEN, Bayer AG, AstraZeneca, Valent Pharmaceuticals LLC, Sanofi-Aventis, Pfizer Inc., Novartis International AG

표 목록 (Tables)

List of Tables Table 1 Global Prostate Cancer Market Value, By Therapy, 2025, 2029 & 2033 (US$ Billion)

Table 2 Global Prostate Cancer Market Value, By Route of Administration, 2025, 2029 & 2033 (US$ Billion)

Table 3 Global Prostate Cancer Market Value, By Distribution Channel, 2025, 2029 & 2033 (US$ Billion)

Table 4 Global Prostate Cancer Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)

Table 5 Global Prostate Cancer Market Value, By Therapy, 2025, 2029 & 2033 (US$ Billion)

Table 6 Global Prostate Cancer Market Value, By Therapy, 2022-2033 (US$ Billion)

Table 7 Global Prostate Cancer Market Value, By Route of Administration, 2025, 2029 & 2033 (US$ Billion)

Table 8 Global Prostate Cancer Market Value, By Route of Administration, 2022-2033 (US$ Billion)

Table 9 Global Prostate Cancer Market Value, By Distribution Channel, 2025, 2029 & 2033 (US$ Billion)

Table 10 Global Prostate Cancer Market Value, By Distribution Channel, 2022-2033 (US$ Billion)

Table 11 Global Prostate Cancer Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)

Table 12 Global Prostate Cancer Market Value, By Region, 2022-2033 (US$ Billion)

Table 13 North America Prostate Cancer Market Value, By Therapy, 2022-2033 (US$ Billion)

Table 14 North America Prostate Cancer Market Value, By Route of Administration, 2022-2033 (US$ Billion)

Table 15 North America Prostate Cancer Market Value, By Distribution Channel, 2022-2033 (US$ Billion)

Table 16 North America Prostate Cancer Market Value, By Country, 2022-2033 (US$ Billion)

Table 17 Europe Prostate Cancer Market Value, By Therapy, 2022-2033 (US$ Billion)

Table 18 Europe Prostate Cancer Market Value, By Route of Administration, 2022-2033 (US$ Billion)

Table 19 Europe Prostate Cancer Market Value, By Distribution Channel, 2022-2033 (US$ Billion)

Table 20 Europe Prostate Cancer Market Value, By Country, 2022-2033 (US$ Billion)

Table 21 Asia-Pacific Prostate Cancer Market Value, By Therapy, 2022-2033 (US$ Billion)

Table 22 Asia-Pacific Prostate Cancer Market Value, By Route of Administration, 2022-2033 (US$ Billion)

Table 23 Asia-Pacific Prostate Cancer Market Value, By Distribution Channel, 2022-2033 (US$ Billion)

Table 24 Asia-Pacific Prostate Cancer Market Value, By Country, 2022-2033 (US$ Billion)

Table 25 South America Prostate Cancer Market Value, By Therapy, 2022-2033 (US$ Billion)

Table 26 South America Prostate Cancer Market Value, By Route of Administration, 2022-2033 (US$ Billion)

Table 27 South America Prostate Cancer Market Value, By Distribution Channel, 2022-2033 (US$ Billion)

Table 28 South America Prostate Cancer Market Value, By Country, 2022-2033 (US$ Billion)

Table 29 Middle East and Africa Prostate Cancer Market Value, By Therapy, 2022-2033 (US$ Billion)

Table 30 Middle East and Africa Prostate Cancer Market Value, By Route of Administration, 2022-2033 (US$ Billion)

Table 31 Middle East and Africa Prostate Cancer Market Value, By Distribution Channel, 2022-2033 (US$ Billion)

Table 32 Middle East and Africa Prostate Cancer Market Value, By Country, 2022-2033 (US$ Billion)

Table 33 Bayer AG: Overview

Table 34 Bayer AG: Product Portfolio

Table 35 Bayer AG: Key Developments

Table 36 Johnson & Johnson: Overview

Table 37 Johnson & Johnson: Product Portfolio

Table 38 Johnson & Johnson: Key Developments

Table 39 Novartis Pharmaceuticals Corporation: Overview

Table 40 Novartis Pharmaceuticals Corporation: Product Portfolio

Table 41 Novartis Pharmaceuticals Corporation: Key Developments

Table 42 Blue Earth Diagnostics, Inc.: Overview

Table 43 Blue Earth Diagnostics, Inc.: Product Portfolio

Table 44 Blue Earth Diagnostics, Inc.: Key Developments

Table 45 Telix Pharmaceuticals (US) Inc.: Overview

Table 46 Telix Pharmaceuticals (US) Inc.: Product Portfolio

Table 47 Telix Pharmaceuticals (US) Inc.: Key Developments

Table 48 Pfizer Inc.: Overview

Table 49 Pfizer Inc.: Product Portfolio

Table 50 Pfizer Inc.: Key Developments

Table 51 Astellas Pharma US, Inc.: Overview

Table 52 Astellas Pharma US, Inc.: Product Portfolio

Table 53 Astellas Pharma US, Inc.: Key Developments

Table 54 Sanofi-Aventis U.S. LLC.: Overview

Table 55 Sanofi-Aventis U.S. LLC.: Product Portfolio

Table 56 Sanofi-Aventis U.S. LLC.: Key Developments

그림 목록 (Figures)

List of Figures Figure 1 Global Prostate Cancer Market Value, 2022-2033 (US$ Billion)

Figure 2 Global Prostate Cancer Market Share, By Therapy, 2024 & 2033 (%)

Figure 3 Global Prostate Cancer Market Share, By Route of Administration, 2024 & 2033 (%)

Figure 4 Global Prostate Cancer Market Share, By Distribution Channel, 2024 & 2033 (%)

Figure 5 Global Prostate Cancer Market Share, By Region, 2024 & 2033 (%)

Figure 6 Global Prostate Cancer Market Y-o-Y Growth, By Therapy, 2023-2033 (%)

Figure 7 Chemotherapy Prostate Cancer Market Value, 2022-2033 (US$ Billion)

Figure 8 Hormonal Therapy Prostate Cancer Market Value, 2022-2033 (US$ Billion)

Figure 9 Immunotherapy Prostate Cancer Market Value, 2022-2033 (US$ Billion)

Figure 10 Targeted Therapy Prostate Cancer Market Value, 2022-2033 (US$ Billion)

Figure 11 Global Prostate Cancer Market Y-o-Y Growth, By Route of Administration, 2023-2033 (%)

Figure 12 By Oral Route Route of Administration in Global Prostate Cancer Market Value, 2022-2033 (US$ Billion)

Figure 13 By Intravenous (IV) Route Route of Administration in Global Prostate Cancer Market Value, 2022-2033 (US$ Billion)

Figure 14 Other routes Route of Administration in Global Prostate Cancer Market Value, 2022-2033 (US$ Billion)

Figure 15 Global Prostate Cancer Market Y-o-Y Growth, By Distribution Channel, 2023-2033 (%)

Figure 16 Hospital Pharmacies Distribution Channel in Global Prostate Cancer Market Value, 2022-2033 (US$ Billion)

Figure 17 Retail Pharmacies Distribution Channel in Global Prostate Cancer Market Value, 2022-2033 (US$ Billion)

Figure 18 Online Pharmacies Distribution Channel in Global Prostate Cancer Market Value, 2022-2033 (US$ Billion)

Figure 19 Global Prostate Cancer Market Y-o-Y Growth, By Region, 2023-2033 (%)

Figure 20 North America Prostate Cancer Market Value, 2022-2033 (US$ Billion)

Figure 21 North America Prostate Cancer Market Share, By Therapy, 2024 & 2033 (%)

Figure 22 North America Prostate Cancer Market Share, By Route of Administration, 2024 & 2033 (%)

Figure 23 North America Prostate Cancer Market Share, By Distribution Channel, 2024 & 2033 (%)

Figure 24 North America Prostate Cancer Market Share, By Country, 2024 & 2033 (%)

Figure 25 Europe Prostate Cancer Market Value, 2022-2033 (US$ Billion)

Figure 26 Europe Prostate Cancer Market Share, By Therapy, 2024 & 2033 (%)

Figure 27 Europe Prostate Cancer Market Share, By Route of Administration, 2024 & 2033 (%)

Figure 28 Europe Prostate Cancer Market Share, By Distribution Channel, 2024 & 2033 (%)

Figure 29 Europe Prostate Cancer Market Share, By Country, 2024 & 2033 (%)

Figure 30 Asia-Pacific Prostate Cancer Market Value, 2022-2033 (US$ Billion)

Figure 31 Asia-Pacific Prostate Cancer Market Share, By Therapy, 2024 & 2033 (%)

Figure 32 Asia-Pacific Prostate Cancer Market Share, By Route of Administration, 2024 & 2033 (%)

Figure 33 Asia-Pacific Prostate Cancer Market Share, By Distribution Channel, 2024 & 2033 (%)

Figure 34 Asia-Pacific Prostate Cancer Market Share, By Country, 2024 & 2033 (%)

Figure 35 South America Prostate Cancer Market Value, 2022-2033 (US$ Billion)

Figure 36 South America Prostate Cancer Market Share, By Therapy, 2024 & 2033 (%)

Figure 37 South America Prostate Cancer Market Share, By Route of Administration, 2024 & 2033 (%)

Figure 38 South America Prostate Cancer Market Share, By Distribution Channel, 2024 & 2033 (%)

Figure 39 South America Prostate Cancer Market Share, By Country, 2024 & 2033 (%)

Figure 40 Middle East and Africa Prostate Cancer Market Value, 2022-2033 (US$ Billion)

Figure 41 Middle East and Africa Prostate Cancer Market Share, By Therapy, 2024 & 2033 (%)

Figure 42 Middle East and Africa Prostate Cancer Market Share, By Route of Administration, 2024 & 2033 (%)

Figure 43 Middle East and Africa Prostate Cancer Market Share, By Distribution Channel, 2024 & 2033 (%)

Figure 44 Bayer AG: Financials

Figure 45 Johnson & Johnson: Financials

Figure 46 Novartis Pharmaceuticals Corporation: Financials

Figure 47 Blue Earth Diagnostics, Inc.: Financials

Figure 48 Telix Pharmaceuticals (US) Inc.: Financials

Figure 49 Pfizer Inc.: Financials

Figure 50 Astellas Pharma US, Inc.: Financials

Figure 51 Sanofi-Aventis U.S. LLC.: Financials

세계 전립선암 시장 – 2023-2030

Global Prostate Cancer Market - 2023-2030